Role of fludarabine in hematological malignancies (Q34571439)

3 August 2017

1 reference

title

Role of fludarabine in hematological malignancies (English)

1 reference

3 August 2017

Marco Montillo

1

1 reference

3 August 2017

Francesca Ricci

series ordinal

2

1 reference

3 August 2017

Alessandra Tedeschi

series ordinal

3

1 reference

3 August 2017

1 September 2006

1 reference

Expert Review of Anticancer Therapy

3 August 2017

1 reference

3 August 2017

6

1 reference

3 August 2017

9

1 reference

3 August 2017

1141-1161

1 reference

Metabolism and action of purine nucleoside analogs

3 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Cellular and clinical pharmacology of fludarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Fludarabine phosphate. A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

The bioavailability of oral fludarabine phosphate is unaffected by food

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Evaluating treatment strategies in chronic lymphocytic leukemia: use of quality-adjusted survival analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Rituximab therapy of patients with B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Rituximab dose-escalation trial in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Combination of Fludarabine and Mitoxantrone in Untreated Stages III and IV Low-Grade Lymphoma: S9501

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Mantle cell lymphoma: a biological and therapeutic paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Fludarabine therapy in Waldenström's macroglobulinemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Feasibility of fludarabine added to VAD during induction therapy in multiple myeloma: a randomised phase II-study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

De novo acute myeloid leukemia with multilineage dysplasia: treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Infectious and immunosuppressive complications of purine analog therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

Fludarabine therapy in Waldenström's macroglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1141

10.1586/14737140.6.9.1141

21 January 2018

Identifiers

DOI

1 reference

release_el4izj7e5zg4th5uu34oaisfqi

3 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/el4izj7e5zg4th5uu34oaisfqi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference